Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Torvutatug samrotecan · 1 trial · 4 indications
Number of participants with incidence of adverse events and with serious adverse events including changes from baseline in laboratory parameters, vital signs, ECGs, and physical examination.
A DLT is defined as any ≥ Grade 3 treatment-emergent AE that occurs during the DLT evaluation period, not attributable to the underlying disease or extraneous causes (as defined in the protocol)
| Arm | Type | Description |
|---|---|---|
| Module 1: Torvu-sam Monotherapy | EXPERIMENTAL | Torvu-sam Monotherapy |
| Module 2: Torvu-sam + Saruparib | EXPERIMENTAL | Torvu-sam + Saruparib |
| Module 3: Torvu-sam + Bevacizumab | EXPERIMENTAL | Torvu-sam + Bevacizumab |
| Module 4: Torvu-sam + Carboplatin +/- Bevacizumab | EXPERIMENTAL | Torvu-sam + Carboplatin +/- Bevacizumab |
| Module 5: Torvu-sam + Palacaparib +/- Bevacizumab | EXPERIMENTAL | Torvu-sam + Palacaparib +/- Bevacizumab |
| Module 6: Torvu-sam + Pembrolizumab +/- Palacaparib | EXPERIMENTAL | Torvu-sam + Pembrolizumab +/- Palacaparib |
| Name | Type | Description |
|---|---|---|
| Torvutatug samrotecan | DRUG | IV Antibody-drug conjugate |
| Saruparib | DRUG | Oral PARP inhibitor |
| Bevacizumab | DRUG | IV Monoclonal antibody |
| Carboplatin | DRUG | IV Alkylating agent |
| Palacaparib | DRUG | Oral PARP inhibitor |
| Pembrolizumab | DRUG | IV Biologic |
Core Inclusion Criteria: * Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. * Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of sample...
Top 20 of 59 competitors
Torvutatug samrotecan is an investigational small molecule being developed for the treatment of ovarian cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in clinical trials.
Torvutatug samrotecan is a small molecule, but its specific molecular target has not been disclosed in the available information. The drug is being studied in a Phase 1 clinical trial for solid tumors, including ovarian cancer, but the exact mechanism of action is not publicly detailed.
Torvutatug samrotecan is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. AstraZeneca is conducting clinical trials to evaluate the drug's safety and efficacy in patients with solid tumors.
Torvutatug samrotecan is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies such as the FDA. The ongoing Phase 1 trial is recruiting participants to study the drug as a monotherapy and in combination therapy for solid tumors.
Torvutatug samrotecan is being studied in a Phase 1/IIa clinical trial with the identifier NCT05797168. This trial is recruiting 602 participants with solid tumors, including ovarian cancer, lung adenocarcinoma, endometrial cancer, and lung squamous cell carcinoma. The study is being conducted across multiple countries, including the United States, Australia, Canada, China, Germany, Israel, Japan, South Korea, Spain, Taiwan, Turkey, and the United Kingdom.
Yes, Torvutatug samrotecan is also known as AZD5335. The clinical trial NCT05797168, titled 'Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors,' is evaluating this drug. The trial is currently recruiting patients with various solid tumors, including ovarian cancer.